Indevus

Indevus Pharmaceuticals, Inc. (collectively, the "Healthcare Companies").

Bill Singer: Insider Trading: Frequent Flyers, Potatoes and Macy's Bill Singer 2010

Indevus Pharmaceuticals, Inc. (collectively, the "Healthcare Companies").

Bill Singer: Insider Trading: Frequent Flyers, Potatoes and Macy's Bill Singer 2010

Last year, Endo Pharmaceuticals Inc. paid $370 million, or $4.50 in cash for Indevus Pharmaceuticals Inc, but agreed to pay an additional $3 per share if the FDA approves two Indevus drugs and sales cross certain milestones.

Genzyme Mulls Its Deal Options Gina Chon 2010

The specialty pharmaceutical company offered $370 million, or $4.50 a share, for Indevus, which represents a 45% premium to the company's stock price Monday.

Endo Will Buy Indevus in $637 Million Deal 2009

Endo Chief Executive David Holveck said the company believed the expansion of its produce lines showed "significant growth potential because of the therapeutic value of the Indevus product portfolio."

Endo Will Buy Indevus in $637 Million Deal 2009

[The company announced Jan. 5 it will acquire Indevus Pharmaceuticals.]

Good Thoughts Lauren R. Rublin 2009

Priced at 25 cents, the contracts make money if Indevus shares drop below $2.25.

Case for Buying Eli Lilly Calls 2008

Indevus fell 30 cents, or 6.8%, to $4.10 in 4 p.m.

Case for Buying Eli Lilly Calls 2008

With Indevus awaiting approval for its Nebido drug, options traders appeared bearish on the company and bought July $2.50 puts.

Case for Buying Eli Lilly Calls 2008

Indevus Pharmaceuticals slid 2.84, or 69%, to 1.26, after the Lexington, Mass., biotechnology company said the Food and Drug Administration requested more safety data for its injectable testosterone medication, Nebido, delaying the drug's approval.

MBIA and Ambac Slide 2008